Who Paid My Doc
A Phase Iib, Randomized, Partially Blind, Active Controlled, Dose-Rang
Research payments
$816,395
Through program year 2024, $816,395 in research payments was reported against A Phase Iib, Randomized, Partially Blind, Active Controlled, Dose-Rang, across 245 payments, paid by ViiV Healthcare Company.
- Paid by
- ViiV Healthcare Company
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $125,561 | 36 |
| 2023 | Research | $95,381 | 53 |
| 2022 | Research | $215,936 | 83 |
| 2021 | Research | $379,518 | 73 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
6 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Moti Ramgopal Fort Lauderdale, FL Named on 46 payments
- William Towner Los Angeles, CA Named on 29 payments
- Sara Bares Omaha, NE Named on 28 payments
- Charlotte-Paige Rolle Orlando, FL Named on 21 payments
- Paul Benson Berkley, MI Named on 16 payments
- Carl Fichtenbaum Cincinnati, OH Named on 10 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.